Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15307543 | 1.00 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL2533818 | 1.00 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL3343090 | 1.00 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL6689012 | 1.00 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL1692473 | 1.00 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL4071198 | 1.00 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL9458781 | 1.00 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL6580821 | 0.98 | EPHX1 (0.64) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL5598408 | 0.86 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL5598863 | 0.86 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279586-B2 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE SERIPHARM (FR) | 2007-10-09 | — | — | US | claimed |
| US-20040220256-A1 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | CHANTELOUP LUC (FR) | 2004-11-04 | — | — | US | claimed |
| EP-0603176-B2 | beta-PHENYLISOSERINE-(2R,3S), SALTS, PREPARATION AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2003-06-18 | — | — | EP | claimed |
| US-20020068833-A1 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE SERIPHARM | 2002-06-06 | — | — | US | claimed |
| EP-0863887-B1 | INTERMEDIARY COMPOUNDS FOR THE HEMISYNTHESIS OF TAXANES AND PREPARATION PROCESSES THEREFOR | SERIPHARM (FR) | 2002-01-23 | — | — | EP | claimed |
| US-6265587-B1 | REACTING ARYLGLYCIDATE WITH A NITRILE TO OBTAIN B-ARYLISOSERINE DERIVATIVE AND TREATING PRODUCT WITH LEWIS ACID TO OBTAIN OXAZOLINE COMPOUND | SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE SERIPHARM (FR) | 2001-07-24 | — | — | US | claimed |
| EP-0863887-A1 | INTERMEDIARY COMPOUNDS FOR THE HEMISYNTHESIS OF TAXANES AND PREPARATION PROCESSES THEREFOR | Societé d'Etude et de Recherche en Ingenierie Pharmaceutique Seripharm (FR) | 1998-09-16 | — | — | EP | claimed |
| US-5684168-A | β-phenylisoserine-(2R,3S), salts, preparation and use thereof | RHONE-POULENC RORER S.A. (FR) | 1997-11-04 | — | — | US | claimed |
| EP-0603176-B1 | beta-PHENYLISOSERINE-(2R,3S), SALTS, PREPARATION AND USE THEREOF | RHONE POULENC RORER SA (FR) | 1997-08-20 | — | — | EP | claimed |
| WO-1997015562-A1 | INTERMEDIARY COMPOUNDS FOR THE HEMISYNTHESIS OF TAXANES AND PREPARATION PROCESSES THEREFOR | SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE SERIPHARM (FR) | 1997-05-01 | — | — | WO | claimed |
| US-5359124-A | Reacting benzylamine with cis-beta-phenylglycidic acid yields intermediate for anticarcinogenic taxol derivatives | AVENTIS PHARMA S.A. (FR) | 1994-10-25 | — | — | US | claimed |
| US-5256803-A | Process for the preparation of (2R,3R)-cis)-β-phenylglycidic acid | RHONE-POULENC RORER S.A. (FR) | 1993-10-26 | — | — | US | claimed |
| EP-4065231-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021108683-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-7432383-B2 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE-SERIPHARM (FR) | 2008-10-07 | — | — | US | disclosed |
| US-7279586-B2 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE SERIPHARM (FR) | 2007-10-09 | — | — | US | disclosed |
| WO-1991013066-A3 | METHOD FOR PREPARING CIS-β-PHENYLGLYCIDIC-(2R,3R) ACID | RHONE POULENC RORER SA (FR) | 1991-10-17 | — | — | WO | disclosed |
| WO-1991013066-A2 | METHOD FOR PREPARING CIS-β-PHENYLGLYCIDIC-(2R,3R) ACID | RHONE-POULENC RORER S.A. (FR) | 1991-09-05 | — | — | WO | disclosed |
| WO-1991013066-A2 | METHOD FOR PREPARING CIS-β-PHENYLGLYCIDIC-(2R,3R) ACID | RHONE-POULENC RORER S.A. (FR) | 1991-09-05 | — | — | WO | disclosed |
| WO-1991003466-A1 | SUBSTITUTED QUINOLINES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB (DK) | 1991-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068833-A1 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | DHPS, DOHH, HADH | EPHX1 276/4885TSHR 4437/4885MEN1 531/4885 |
| US-20040220256-A1 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | DHPS, HASPIN, BDNF | EPHX1 358/4885TSHR 4650/4885MEN1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.